Skip to main content
Premium Trial:

Request an Annual Quote

Biotheranostics Settles False Claims Allegations With DOJ for $2M

NEW YORK (GenomeWeb) – The US Department of Justice said on Thursday that Biotheranostics has agreed to pay $2 million to settle allegations that the company improperly billed Medicare for molecular breast cancer tests. 

The DOJ alleged the San Diego-based company promoted and performed its Breast Cancer Index test on breast cancer patients who had not been in remission for five years and who had not been taking tamoxifen. Biotheranostics then billed the Centers for Medicare & Medicaid Services for the tests, although they were unnecessary for those patients, based on published clinical trial data and clinical practice guidelines, DOJ said.

According to Biotheranostics' website, BCI can determine a breast cancer patient's risk of recurrence beyond five years. Using the original tumor biopsy, it evaluates several genes associated with cell proliferation and the estrogen signaling pathway. The test can predict the likelihood of benefit from extended endocrine therapy, the company said.

The DOJ noted that Biotheranostics did not admit to any wrongdoing in the settlement deal. 

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.